This webinar will cover the key steps and considerations involved in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages.
Viatris to receive exclusive global development & commercialization rights to 2 Phase 3 assets as well as the potential to add additional assets in the future.
Gao has more than 25 years of experience in leading various functions including finance, audit, investment, project management, compliance and board office.
Multi-million-dollar investment in state-of-the-art technology and equipment is part of an overall renovation and expansion project at its main campus.
To leverage Immatics' TCR platform with Moderna's mRNA technology across therapeutic modalities including bispecifics, cell therapy and cancer vaccines.